CLRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cellectar Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.12−0.02 (-1.75%)
Close on Oct 19, 2026
- Market cap
- $13.70M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.38 (−75.11%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $13.70M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.46
- Dividend yield
- –
- Free cash flow yield
- -168.79%
Fundamentals
- Net income
- -$22.32M
- EPS, diluted
- -$8.35
- Free cash flow
- -$23.12M
- Book value per share
- $2.44
- Diluted shares
- 12M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Operating income
-$23.53M
Net income
-$22.32M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months